Generation Bio Co. (NASDAQ:GBIO – Get Rating) COO Antoinette Paone sold 4,610 shares of Generation Bio stock in a transaction on Thursday, September 15th. The shares were sold at an average price of $5.32, for a total value of $24,525.20. Following the sale, the chief operating officer now directly owns 2,828 shares of the company’s stock, valued at approximately $15,044.96. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
Generation Bio Stock Down 1.5 %
NASDAQ GBIO opened at $5.13 on Wednesday. The company has a market capitalization of $302.73 million, a price-to-earnings ratio of -2.16 and a beta of 1.96. The stock’s 50-day simple moving average is $6.33 and its two-hundred day simple moving average is $6.38. Generation Bio Co. has a twelve month low of $3.96 and a twelve month high of $26.70.
Generation Bio (NASDAQ:GBIO – Get Rating) last released its quarterly earnings data on Thursday, August 4th. The company reported ($0.66) EPS for the quarter, missing the consensus estimate of ($0.63) by ($0.03). On average, equities analysts expect that Generation Bio Co. will post -2.63 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Wall Street Analyst Weigh In
GBIO has been the topic of a number of research reports. Wedbush restated an “outperform” rating and set a $24.00 price target on shares of Generation Bio in a research report on Friday, August 5th. JMP Securities raised their price target on Generation Bio from $10.00 to $11.00 and gave the company a “market outperform” rating in a research report on Monday, August 8th. Finally, Needham & Company LLC lowered their price target on Generation Bio from $27.00 to $23.00 and set a “buy” rating on the stock in a research report on Friday, August 5th. Two analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $19.33.
About Generation Bio
Generation Bio Co, a genetic medicines company, develops therapies for the treatment of rare and prevalent diseases. The company provides a portfolio of programs, including programs for rare and prevalent diseases of the liver and retina. It also focuses on the diseases of skeletal muscle, central nervous system, and oncology.
- Get a free copy of the StockNews.com research report on Generation Bio (GBIO)
- 3 Airline Stocks Stuck in a Holding Pattern
- Roku Stock is Down but Not Out
- If You’re Hungry for Value, Take a Bite on Ruth’s Hospitality Grp
- Is Ford Rolling To A Rebound After Its Q3 Warning
- Has AMD stock stock fallen too far?
Receive News & Ratings for Generation Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Generation Bio and related companies with MarketBeat.com's FREE daily email newsletter.